LabTech launches MicroStreak in US
Wednesday, 11 June, 2008
Adelaide-based diagnostics company LabTech Systems (ASX: LBT) has launched its MicroStreak technology in the US.
The company held a launch for the product, which has been named PREVI Isola by licensees bioMerieux, at the American Society of Microbiology meeting held in Boston this week.
MicroStreak is a new method of microbiology processing, automating the streaking of agar plates to test samples. The technology was already launched in Europe in April.
LabTech has earned $4.9 million in licence fees to date.
For a full report on the MicroStreak, see the July/August edition of Australian Life Scientist.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
